Medicon Valley Biomedical Newsletter

Santaris Pharma A/S has completed a new EUR 20 million private investment round. Gilde Healthcare Partners, a new investor in the Company, contributed EUR 7.5 million of the financing, with the remain...

BioInvent AB has announced that it has decided to designate a new clinical drug candidate, BI-505. The new drug candidate comes from BioInvent's research programme within the area of apoptosis to ...

CMC Biopharmaceuticals A/S has announced an agreement to buy the biologics development and manufacturing operation from Eli Lilly. CMC will purchase the biologics facility in Bothell, Washington State...

Exiqon A/S and Oncotech Inc have announced that they have entered into a binding Letter of Intent under which Exiqon will acquire Oncotech, a California based leading supplier of extreme drug resistan...

Mantle cell lymphoma, MCL, is an aggressive form of blood cancer that most commonly afflicts older men. Accurate and early diagnosis is crucial to select an optimal treatment and to increase the chanc...

Novozymes A/S and Millipore Corporation have agreed to develop, market, and sell new, animal-free cell culture supplements for biopharmaceutical manufacturing. The new products, to be marketed under t...

Symphogen A/S, who focuses on development of a novel type of drugs based on antibodies, has won the title of best growth company in the biotech business at the Ernst & Young's Entrepreneur of ...